Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from Analysts at Stifel Nicolaus

Equities researchers at Stifel Nicolaus began coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report issued on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $49.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 88.46% from the stock’s current price.

ORKA has been the topic of several other reports. HC Wainwright assumed coverage on shares of Oruka Therapeutics in a research report on Monday. They issued a “buy” rating and a $45.00 price target on the stock. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target on the stock. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Wedbush began coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, TD Cowen began coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating for the company. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Trading Down 8.6 %

NASDAQ:ORKA opened at $26.00 on Friday. The firm has a market capitalization of $31.46 million, a P/E ratio of -4.33 and a beta of 0.89. Oruka Therapeutics has a 1 year low of $18.72 and a 1 year high of $53.88.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($25.92) earnings per share (EPS) for the quarter. Research analysts forecast that Oruka Therapeutics will post -1.62 EPS for the current year.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.